Alpa Laboratories Ltd

Alpa Laboratories Ltd

₹ 111 0.16%
22 Nov - close price
About

Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]

Key Points

Business Overview:[1]
ALL is a WHO-GMP and ISO 9001:2000 certified company. It manufactures a wide range of Pharmaceutical Finished Dosage Forms under its own brand and for other Indian and multinational companies. The product range includes a wide variety of ethical, generic, and over-the-counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use

  • Market Cap 233 Cr.
  • Current Price 111
  • High / Low 145 / 69.9
  • Stock P/E 11.2
  • Book Value 83.0
  • Dividend Yield 0.00 %
  • ROCE 13.7 %
  • ROE 11.2 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 45.1% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 7.12% over past five years.
  • Company has a low return on equity of 9.02% over last 3 years.
  • Earnings include an other income of Rs.19.6 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
26.26 29.33 25.50 22.42 13.54 27.31 29.16 25.43 32.39 27.31 23.61 21.44 24.94
22.73 25.61 26.86 21.00 19.28 24.68 19.90 26.58 29.07 24.85 20.10 20.90 21.67
Operating Profit 3.53 3.72 -1.36 1.42 -5.74 2.63 9.26 -1.15 3.32 2.46 3.51 0.54 3.27
OPM % 13.44% 12.68% -5.33% 6.33% -42.39% 9.63% 31.76% -4.52% 10.25% 9.01% 14.87% 2.52% 13.11%
2.70 2.20 3.72 1.61 6.38 2.69 -0.76 4.47 2.95 3.55 3.97 5.18 6.91
Interest 0.06 0.08 0.07 0.03 0.08 0.07 0.04 0.02 0.04 0.03 0.30 0.05 0.06
Depreciation 0.42 0.43 0.50 0.34 0.36 0.10 0.53 0.28 0.49 0.66 0.52 0.54 0.53
Profit before tax 5.75 5.41 1.79 2.66 0.20 5.15 7.93 3.02 5.74 5.32 6.66 5.13 9.59
Tax % 0.00% 0.00% 304.47% 0.00% 0.00% 0.00% 41.74% 0.00% 0.00% 14.85% 46.70% 0.00% 20.44%
5.75 5.41 -3.66 2.66 0.20 5.14 4.62 3.03 5.74 4.53 3.55 5.12 7.63
EPS in Rs 2.73 2.57 -1.74 1.26 0.10 2.44 2.20 1.44 2.73 2.15 1.69 2.43 3.63
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
56 56 57 53 63 62 77 85 97 112 93 109 97
53 51 54 47 56 57 76 79 90 101 85 100 88
Operating Profit 3 6 3 7 7 4 1 6 8 11 8 9 10
OPM % 5% 10% 6% 13% 11% 7% 2% 7% 8% 10% 9% 8% 10%
0 1 2 6 4 5 5 0 4 11 9 14 20
Interest 2 2 2 1 2 1 1 0 0 0 0 0 0
Depreciation 5 9 6 1 1 1 1 1 1 2 1 2 2
Profit before tax -3 -5 -3 11 9 7 5 5 11 20 16 21 27
Tax % 36% 4% -48% 27% 34% 27% 36% 20% 33% 28% 21% 19%
-4 -5 -1 8 6 5 3 4 7 14 13 17 21
EPS in Rs -2.08 -2.45 -0.67 3.68 2.85 2.27 1.40 1.94 3.45 6.72 6.00 7.98 9.90
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 7%
5 Years: 7%
3 Years: 4%
TTM: -15%
Compounded Profit Growth
10 Years: 18%
5 Years: 45%
3 Years: 49%
TTM: 12%
Stock Price CAGR
10 Years: 22%
5 Years: 48%
3 Years: 23%
1 Year: 13%
Return on Equity
10 Years: 6%
5 Years: 8%
3 Years: 9%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 21 21 21 21 21 21 21 21 21 21 21 21 21
Reserves 72 67 66 73 77 82 85 89 96 111 124 141 154
17 23 29 24 11 6 2 0 0 6 3 5 3
14 15 13 27 20 17 21 21 33 28 30 25 32
Total Liabilities 125 127 128 145 129 127 129 131 150 165 178 192 210
80 73 5 5 5 6 6 6 7 9 7 11 11
CWIP 0 0 0 0 0 0 0 1 2 0 0 0 0
Investments 0 0 10 22 23 41 59 68 62 86 90 109 128
45 54 113 118 100 79 64 56 80 70 81 72 71
Total Assets 125 127 128 145 129 127 129 131 150 165 178 192 210

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3 8 -2 -25 -8 -7 -1 18 -1 2 10 4
-4 -2 37 -7 1 -16 -15 -11 6 -16 1 -12
2 4 7 -6 -2 4 -5 -1 -0 5 -3 2
Net Cash Flow 0 10 42 -37 -9 -19 -20 5 4 -8 8 -6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 127 130 156 234 169 151 141 105 133 124 186 138
Inventory Days 132 148 76 196 131 140 105 90 102 81 84 73
Days Payable 85 121 91 244 140 130 99 98 152 78 100 63
Cash Conversion Cycle 174 157 141 187 160 161 148 97 83 127 170 149
Working Capital Days 187 169 178 390 256 234 194 121 137 136 157 150
ROCE % -1% -3% 0% 10% 11% 7% 4% 7% 7% 9% 11% 14%

Shareholding Pattern

Numbers in percentages

23 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
56.66% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29% 57.29%
0.09% 0.56% 0.21% 0.14% 0.00% 0.00% 0.00% 0.11% 0.95% 0.50% 0.36% 0.74%
0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
43.20% 42.15% 42.50% 42.56% 42.70% 42.70% 42.70% 42.59% 41.74% 42.21% 42.35% 41.97%
No. of Shareholders 16,11418,77518,79618,84019,09419,13718,74518,56518,68218,69018,11618,885

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents